David Veitch, Basilea CEO

Swiss phar­ma Basilea sheds yet an­oth­er on­col­o­gy pro­gram as an­ti-in­fec­tives piv­ot plows for­ward

Act­ing on its plans to dis­card its on­col­o­gy pipeline, Swiss com­pa­ny Basilea Phar­ma­ceu­ti­ca has de­cid­ed to sell its can­cer drug BAL0891 to Ko­re­an biotech Sil­la­Jen for $14 mil­lion up­front.

Basilea had an­nounced its de­ci­sion to ditch its on­col­o­gy pipeline in Feb­ru­ary, as a part of a re­or­ga­ni­za­tion of its R&D pipeline around an­ti-in­fec­tives, in­clud­ing its two ap­proved drugs in that space. Tues­day’s sale will al­so fetch Basilea ad­di­tion­al mile­stone pay­ments of up to $320 mil­lion and tiered roy­al­ties on net sales.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.